Celera snaps up Atria; closes BHL deal
This article was originally published in Clinica
Executive Summary
In a bid to expand its reach into new diagnostic markets, Celera has acquired Atria Genetics, a privately-held developer of human leukocyte antigen (HLA) tests for identifying appropriate bone marrow donors.